Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02446093 · ClinicalTrials.gov registry record · Phase 2
Neoadjuvant CAN-2409 in Combination With Chemoradiation or SBRT for Borderline Resectable Pancreatic Adenocarcinoma
A Phase 2 study of Borderline Resectable Pancreatic Adenocarcinoma, sponsored by Candel Therapeutics.
- Active
- Registry status
- Phase 2
- Development phase
- 54
- Enrollment target
- 3
- Study locations
NCT02446093: Active Phase 2 study of Borderline Resectable Pancreatic Adenocarcinoma, sponsored by Candel Therapeutics.
NCT02446093 is a Phase 2 study of Borderline Resectable Pancreatic Adenocarcinoma that is active but no longer recruiting, run by Candel Therapeutics. The registered enrollment target is 54 participants, above the 44-participant average among 7 other Borderline Resectable Pancreatic Adenocarcinoma trials with a reported enrollment target (23% higher). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02446093, a Phase 2 study of Borderline Resectable Pancreatic Adenocarcinoma, is active but no longer recruiting, sponsored by Candel Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 54 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to characterize the safety, preliminary efficacy, and immune biologic activity of CAN-2409 + prodrug (valacyclovir or acyclovir) in subjects with borderline resectable pancreatic cancer who are being treated with neoadjuvant chemoradiation (CR) or stereotactic body radiation therapy (SBRT). The Standard of Care (SOC) Control arm will be used as a benchmark for informal comparisons of efficacy, safety, and biomarkers.
Conditions Studied
Interventions
- RADIATION Chemoradiation
- PROCEDURE Surgery
- RADIATION Stereotactic body radiation therapy
- BIOLOGICAL Aglatimagene besadenovec
Study Locations (3)
Florida
- Lee Health/Regional Cancer Center - Fort Myers
Ohio
- Ohio State University - Columbus
Other
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran - Mexico City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2015-10 |
| Est. Completion | 2026-07 |
| Phase | Phase 2 |
What the registry record for NCT02446093 still lists
NCT02446093 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 54 participants, a relatively small participant target, above the 44-participant average among 7 other Borderline Resectable Pancreatic Adenocarcinoma trials with a reported enrollment target (23% higher).
The record links to 1 condition, with Borderline Resectable Pancreatic Adenocarcinoma appearing as the primary indexed condition, and to 4 interventions - of which Chemoradiation is the first listed.
NCT02446093 reports a single indexed study location in Florida, Ohio, Other.
Frequently Asked Questions
What is clinical trial NCT02446093 about?
NCT02446093 is a clinical study titled "Neoadjuvant CAN-2409 in Combination With Chemoradiation or SBRT for Borderline Resectable Pancreatic Adenocarcinoma". The purpose of this study is to characterize the safety, preliminary efficacy, and immune biologic activity of CAN-2409 + prodrug (valacyclovir or acyclovir) in subjects with borderline resectable pancreatic cancer who are being treated with neoadjuvant chemoradiation (CR) or stereotactic body radia...
What is the current status of trial NCT02446093?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 54 participants. The study started on 2015-10. Estimated completion is 2026-07.
What conditions does trial NCT02446093 study?
This clinical trial studies the following conditions: Borderline Resectable Pancreatic Adenocarcinoma.
What interventions are being tested in trial NCT02446093?
The interventions under investigation include: Chemoradiation (RADIATION), Surgery (PROCEDURE), Stereotactic body radiation therapy (RADIATION), Aglatimagene besadenovec (BIOLOGICAL).
Who is sponsoring clinical trial NCT02446093?
This trial is sponsored by Candel Therapeutics, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02446093 being conducted?
This trial has 3 study locations across Florida, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Borderline Resectable Pancreatic Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Neoadjuvant Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma
RECRUITING · Phase 2
-
Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic Cancer
ACTIVE NOT RECRUITING · Phase 2
-
New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Cancer, PIONEER-Panc Study
ACTIVE NOT RECRUITING · Phase 2
-
Study of Paclitaxel Protein Bound + Gemcitabine + Cisplatin + Hydrochloroquine as Treatment in Untreated Pancreas Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Zimberelimab and Quemliclustat in Combination With Chemotherapy for the Treatment of Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma
RECRUITING · Phase 1
-
PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01269853 · 54 participants · Phase 1
Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA
- NCT02390752 · 54 participants · Phase 1
Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
- NCT02991248 · 54 participants · NA
Improve Dynamic Lateral Balance of Humans With SCI
- NCT02993900 · 54 participants · NA
Image-Guided Gynecologic Brachytherapy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia